New Staph-Fighting skin regimen shows promise in High-Risk community
NCT ID NCT06210594
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a combination of topical antibiotics and antiseptic washes could reduce staph bacteria on the skin of Native American adults living on or near tribal lands. Participants were at high risk for staph infections due to diabetes, obesity, or recent infections. The trial compared the biomedical regimen plus education and household supplies to education and supplies alone, measuring staph carriage and infection rates.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Mupirocin (Bactroban) + Nozin + chlorhexidine gluconate (Hibiclens)
- What this could lead to
- If successful, this approach could reduce staph infections in high-risk communities by lowering the amount of staph bacteria on the skin.
- What could go wrong
- This is a small, completed Phase 4 trial with only 78 participants, so results may not apply to broader populations. The regimen requires ongoing use, and long-term adherence may be challenging.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
78 people
The number who actually took part.
- Started
-
Apr 2024
- Finished
-
Nov 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Native American adult living on or adjacent to the WMA Tribal lands * 18 years of age and older * Lab-confirmed SA carriage at time of enrollment * Ability to provide written informed consent * Ability to comply with follow-up activities * Risk factor for SA-associated infection: Diagnosed with diabetes OR body mass index ≥30 OR documented SSTI or SA infection in the past 3 years Exclusion Criteria: * Immediate family member of study staff * Allergy to citrus or any ingredient in Nozin, Hibiclens, or mupirocin * Without a permanent home (e.g., living in a group home, shelter, or is unhoused) * Use of antibiotics within 30 days prior to the first study visit (time-limited) * Current SA infection (time-limited)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Staphylococcus aureus infection are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Whiteriver Center for Indigenous Health
Whiteriver, Arizona, 85941, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.